Printer Friendly

Research governance lessons from the National Placebo Initiative.

1. Introduction

For at least the last two decades, Canada has been an international leader in research ethics. Canadian scholars have written seminal articles that now fill standard texts in the field. For example, in the authoritative collection Ethical and Regulatory Aspects of Clinical Research, fully eighteen of 86 articles included in the volume were authored in Canada. (1) In the realm of research ethics policy, Canada's contributions are also many. The Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (2) (TCPS), introduced a decade ago and currently under revision, is widely admired for its scope and substance. More recently the Canadian Institutes of Health Research Guidelines for Research Involving Aboriginal People (3) attracted considerable interest as a potential roadmap for effective research partnerships between aboriginal communities and researchers.

The National Placebo Initiative (NPI) was established in 2002 with a mandate to broker consistent guidance on the use of placebos in clinical research in Canada. Although the recommendations set forth in its Final Report (2004) (4) have the potential to renew Canada's role as an international leader in research ethics, they have yet to be acted upon by the Canadian Institutes of Health Research and Health Canada. In this paper we discuss the history of the placebo question in Canada, describe the recommendations made by the NPI, and attempt to identify some of the reasons for their lack of uptake.

2. Historical Background

Since the 1980s, Canada has been at the center of scholarly work on the ethics of randomized controlled trials (RCT). (5) Early work focused on the ethics of randomization. It is widely acknowledged that the physician owes her patient a duty of care that requires the physician to act and advise in accordance with the patient's best medical interests. In a RCT, the participant is allocated by chance to an experimental or control treatment. How, critics asked, could offering a patient enrollment in a RCT ever be consistent with the physician's duty of care? Benjamin Freedman provided the most widely accepted answer to this question with his concept of "clinical equipoise." (6) According to Freedman, a physician may legitimately offer a patient RCT enrollment provided that each of the treatment arms to which she may be allocated is consistent with competent medical care. In other words, clinical equipoise requires that at the start of a RCT [t]here exist ... an honest, professional disagreement among [the community of] expert clinicians about the preferred treatment." (7)

Generally, a placebo control is appropriate when there is no proven treatment for the study condition. However, once proven treatment exists, an active control (i.e., standard treatment) ought to be used. Not only does this ensure that patients enrolled in a clinical trial will not go untreated when a proven therapy is available, but comparison to an active control provides valuable information on comparative efficacy. If the new drug eventually receives regulatory approval, information on comparative efficacy is essential for informed decision making by policy makers, clinicians, and patients.

Clinical equipoise has clear implications for use of placebo controls in RCTs. In a 1990 article in the journal IRB, Freedman laid out circumstances in which a placebo control may be used consistently with clinical equipoise, namely when:

1. there is no standard treatment;

2. standard treatment is no better than placebo;

3. standard treatment is placebo;

4. the net therapeutic advantage of standard treatment has been called into question by new evidence; or,

5. effective treatment exists but is not available due to cost or short supply. (8)

Two further circumstances in which a placebo control is licit are entailed by Freedman's list. First, a placebo control may be used in a population of patients who don't respond to standard treatment, provided no effective second-line treatment exists (there is no standard treatment). Second, a treatment added to a standard regimen might be compared to placebo provided that all patients in the trial receive the standard regimen (no one is denied standard treatment).

The impact of clinical equipoise on research ethics policy has been profound. The Tri-Council Working Group (1994-1998) appealed to clinical equipoise repeatedly in early drafts of the TCPS and used the concept to justify its restrictive stance on placebo controls. For instance, the April 1998 draft of the TCPS states: "The use of placebos in clinical trials is ethically unacceptable where clearly effective therapies or interventions are available." The commentary on this article goes on to say:

Researchers and REBs should be cautious concerning the use of placebos in clinical trials. Such use may be appropriate when a new or currently used intervention is in clinical equipoise with no intervention or a placebo, and when no clearly effective therapy is available for the study population. In the same vein, it is inappropriate to withhold a clearly effective intervention from patients for research purposes, unless it is being compared with another intervention that satisfies the criterion of clinical equipoise.

Given the widespread use of placebo controls in studies supporting applications for licensure of new drugs, this draft provision generated considerable controversy. Many agreed that Canada's research ethics boards would require more specific guidance in order to implement this provision effectively. In 1998, the National Council on Ethics in Human Research (NCEHR), a Canadian non-governmental organization dedicated to improving research ethics board review, sponsored a consensus-seeking roundtable that brought together representatives of universities, funding agencies, government (including Health Canada) and industry to discuss the issue. (9) The meeting resulted in recommended language that was incorporated as article 7.4 in the final version of the TCPS (see Table l). (10)

Although Health Canada participated in the 1998 consensus-seeking roundtable, its Therapeutic Products Directorate (TPD), Canada's drugs regulator, chose not to endorse the TCPS, largely due to the language of article 7.4. Following the lead of the U.S. Food and Drug Administration, TPD chose not to accept the 2000 revision of the Declaration of Helsinki which (similarly) requires that" [a] new method should be tested against ... the best current prophylactic, diagnostic and therapeutic methods." The reasons behind these policy decisions are undoubtedly complex. Central among them are two: first, that a RCT with a placebo control (as opposed to an active control) provides more reliable evidence of the efficacy of a new treatment; and, second, that proven treatment may ethically be withheld from research participants. (11) In place of the TCPS and the Declaration of Helsinki, TPD endorses the International Conference on Harmonization's Guideline on Good Clinical Practice (ICH GCP). (12) ICH GCP is widely interpreted to take a more permissive stance on the use of placebo controls. A related ICH document (E-10) explicitly permits a placebo control in the face of proven treatment, provided that there is no risk of irreversible harm or death to the participants, appropriate measures are taken to ensure their safety, and proper informed consent is obtained. (13)

The emergence of conflicting international guidance on placebo controls has resulted in significant confusion and frustration for researchers, research ethics boards (REBs), sponsors, and regulators. For although the TCPS and ICH GCP are consistent on many fundamental ethical requirements, the documents differ significantly in their stance on the use of placebo controls in RCTs.

3. The National Placebo Initiative

In the fall of 2001, the Canadian Institutes of Health Research (CIHR), Canada's leading funder of health research, and Health Canada jointly launched the NPI with the aim of reconciling conflicting views on placebo use in clinical trials. The main objective of the NPI was to "make recommendations to Health Canada and CIHR regarding a common placebo policy that can be used to inform; a Canadian appendix to the international regulatory guidance document ICH E-10: Choice of a Control Group and Related Issues in Clinical Trials; and a revision of section 7 on clinical trials in the Tri-Council Policy Statement." (14) This was timely as a number of international organizations, including the World Medical Association (WMA) and the Council for International Organizations of Medical Sciences (CIOMS), were in the process of revising their respective guidelines with special attention to the proper use of placebo controls. CIOMS released its revision late in 2002, while WMA issued a series of clarifications and a major revision in October 2008. (15)

The National Placebo Working Committee (NPWC) consisted of twelve members representing various stakeholders, including researchers, the pharmaceutical industry, regulators, research ethics boards, patients, and the public at large. Over a two-year period the NPWC engaged in extensive consultations with scientific, ethical, legal, and regulatory experts, as well as leading figures in the research ethics board (REB) community. Opportunities for broader stakeholder and public involvement in this initiative included a national conference, focus groups, citizen town hall meetings, and online distribution of the Draft Report of the NPWC for comment.

In July 2004 the Report of the National Placebo Working Committee on the Appropriate Use of Placebos in Clinical Trials in Canada (the Final Report) was delivered to Dr. Robert Peterson, Director General of the Therapeutics Products Directorate at Health Canada, and to the Ethics Office of CIHR. The Final Report presents a consensus view on key aspects of the placebo debate. It also Hags for further work a number of issues on which consensus was not reached. The key policy recommendations on which consensus was achieved centered on changes to TCPS article 7.4 to further clarify the circumstances in which the use of a placebo control is permissible (see Table 1).
Table 1

                                 NPWG Recommendations regarding
                                 use of placebo

TCPS Article 7.4                 Amendments to Tri-Council
                                 Policy Statement, Article 7.4

                                 Article 7 should be amended to
                                 read:

The use of placebo controls in   "The use of an active treatment
clinical trials is generally     comparator in a clinical trial
unacceptable when standard       of a new therapy is generally
therapies or interventions are   the appropriate study design
available for a particular       when established effective
patient population. Clinical     therapy or therapies exist for
equipoise is widely regarded as  the population and indication
the moral foundation of the      under study." Additionally,
randomized-controlled trial. In
order for a clinical trial to
proceed ethically, a state of
clinical equipoise must exist
at the trial's inception (see A
above). Consistent with
clinical equipoise, a placebo
may be used as the control
treatment in a clinical trial
in the following
circumstances:

                                 "A placebo comparator is
                                 acceptable in the following
                                 situations:

a. There is no standard          a) There are no established
treatment;                       effective therapies for the
                                 population and for the
                                 indication under study,

b. Standard therapy has been     b) Existing evidence raises
shown to be no better than       substantial doubt regarding the
placebo;                         net therapeutic benefit of
                                 available therapies,

c. Evidence has arisen creating  c) Patients are refractory to
substantial doubt regarding the  the available therapies by
net therapeutic advantage of     virtue of their past treatment
standard therapy;                history or known medical
                                 history

d. Effective treatment is not    d) The study involves adding a
available to patients due to     new investigational therapy to
cost constraints or short        established effective
supply. (This may only be        therapies, (established
applied when background          effective therapy + new therapy
conditions of justice prevail    vs. established effective
within the health care system    therapy + placebo)
in question; for example, a
placebo-controlled trial is not
permissible when effective but
costly treatment is made
available to the rich but
remains unavailable to the poor
or uninsured.)

e. In a population of patients   e) Patients have determined
who are refractory to standard   that the response to the
treatment and for whom no        established effective therapies
standard second-line treatment   for their condition is
exists;                          unsatisfactory to them," *.

f. Testing add-on treatment to   f) Patients have previously
standard therapy when all        refused established effective
subjects in the trial receive    therapies for their condition." *
all treatments that would
normally be prescribed; or

g. Patients have provided an
informed refusal of standard
therapy for a minor condition
for which patients commonly
refuse treatment and when
withholding such therapy will
not lead to undue suffering or
the possibility of irreversible
harm of any magnitude.

* For articles (e) and (f) the determinations of response satisfaction
and refusal of treatment must take place outside of the context of
recruitment for the clinical trial and prior to the offering of trial
participation to the potential subject, and be documented in a
standardised manner. Under these conditions, study subjects would not
necessarily be considered "refractory" to the available therapies since
the choice to discontinue available therapies is based on their own
opinion and values, not those of the clinicians responsible for their
care. As such, regulatory approval of the therapy under investigation
would not necessarily be restricted.


Changes to policy were then to be made by both CIHR and Health Canada. In the case of CIHR, it would endorse the Final Report and bring forth its recommendations to the Interagency Advisory Panel on Research Ethics (PRE), which is charged with amending and updating the TCPS. PRE would then, in consultation with the other major flinders, issue a revision of the TCPS based on the recommendations. Health Canada, for its part, would endorse the Final Report and use its recommendations as the basis for a draft Canadian appendix to ICH E.-10. The result would be a common standard for placebo use in clinical trials in Canada.

After being presented with the Final Report, CIHR and Health Canada diverged significantly in their reaction. CIHR referred the Final Report to its Standing Committee on Ethics (SCE). After some discussion, in November 2004 the SCE endorsed the main recommendations with minor amendments. The SCE's approval was then communicated to Dr. Alan Bernstein, the President of CIHR.

Health Canada's response was dramatically different. Dr. Robert Peterson, Director General of TPD, contacted the chair of the SCE in early 2005 to discuss concerns, which were outlined in a subsequent letter. These included a concern that public consultation on the final recommendations of the NPI was not as extensive as it should have been. A second concern related to the then recent withdrawal of Vioxx from the market. The suggestion was that Vioxx may not have received regulatory approval in the first place had adequate placebo controlled Phase III trials been conducted. The implication was that Health Canada's endorsement of the Final Report would further restrict the use of placebos, thus opening the door to more large-scale adverse events with drugs. In light of these concerns Health Canada asked the SCE to consider modifying or even withdrawing its recommendations to the President.

The SCE reviewed the letter carefully but concluded that the stated concerns did not warrant either modification or withdrawal of its endorsement of the Final Report, and informed Health Canada accordingly. To date, Health Canada has not endorsed the NPI's Final Report, and neither CIHR nor Health Canada has made the recommended policy changes.

4. Lessons for Research Governance in Canada

Although the NPI--to date at least--has failed to harmonize Canadian guidelines on the use of placebos in clinical trials, this recounting is instructive in several respects. The Canadian struggle with the proper role of placebo controls in clinical trials has mirrored international developments. Ever since the publication of ICH GCP in 1996, there has been an on-going struggle on the placebo issue between ICH GCP and the World Medical Association's Declaration of Helsinki. The Declaration of Helsinki is viewed by many as the authoritative international statement on research ethics. Indeed, it is even referenced in the ICH GCP as the source document for ethical principles. Nevertheless, ICH GCP and related documents of ICH (such as E-10) have not adopted the standard on placebo controls articulated in the Declaration of Helsinki. The division in international standards provides an opportunity for regulatory agencies to choose to which standard they will adhere. On October 27, 2008 the US FDA formally abandoned its use of the Declaration of Helsinki for international clinical trials. In its stead, the FDA will take direction only from the ICH GCP. (16) The FDA's move seems hazardous precisely because it undermines the global reach of the Declaration of Helsinki. Commentators worry that it will undermine international ethics standards and may lead to a balkanization of research ethics. (17)

Canada's proximity to the largest drugs market in the world undoubtedly places Health Canada in a precarious position. Clearly, regulatory harmonization between Health Canada and the U.S. FDA has advantages. Information about new drugs gathered in the FDA licensure process could very usefully inform Canadian review of the same products, and could expedite review in some cases. Beyond this, regulatory harmony enhances Canada's ability to compete for and attract international clinical trials, resulting in knowledge and economic benefits. But these benefits come at a cost. Health Canada's decision not to endorse the Declaration of Helsinki only further undermines the document and exacerbates worries about the erosion of international standards in research ethics. Further, harmony with FDA standards comes at the price of perpetuating conflict in the Canadian governance of clinical trials. We believe Health Canada has been remiss in its failure to endorse the entirety of TCPS, thereby promoting a single ethical standard to protect Canadians in research.

The experience of the National Placebo Initiative highlights the importance of the authority and independence of national ethics bodies. In retrospect, NPI did not have the mandate required to get the job done. In merely relying on CIHR and Health Canada to follow its recommendations, it was in a sense too easy for the funders to simply ignore recommendations with which they did not agree. CIHR and Health Canada ought to have been required to respond publicly within a set time frame to recommendations that were not implemented. The wisdom of the NPI being funded by CIHR and Health Canada must also be questioned. The NPI was in some respects a successor to a successful consensus-seeking roundtable on placebos funded by the National Council on Ethics in Human Research. NCEHR does not fund research, and does not have the conflicts of interest that arise when research sponsors assume responsibility for research governance.

In our view, the experience of the NPI highlights the urgent need for the creation of an independent body to set national research ethics policy. Recent moves to create a "Sponsor's Table for Human Research Participant Protection in Canada," a group of organizations with an interest in human research protections in Canada, seem only to intensify conflicts of interest and undermine independence by placing the control of research governance in the hands of federal, provincial, and private sector sponsors of research. (18) We are likely to achieve progress in the governance of research in Canada only when control of the ethical standards for research is wrested from those who have a mandate to fund and promote research. An independent body given the necessary authority to set national policy is the right avenue to create a unified and effective standard to protect all Canadians in research.

Endnotes

(1) Ezekiel J. Emanuel, ed., Ethical and Regulatory Aspects of Clinical Research: Readings and Commentary (Baltimore: Johns Hopkins University Press, 2003).

(2) Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, & Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans (Ottawa: Public Works and Government Services Canada, 1998 with 2000, 2002, 2005 amendments), online: Interagency Advisory Panel on Research Ethics (PRE) <http://www.pre.ethics.gc.ca/english/policystatement/policystatement.cfm> [TCPS].

(3) See Aboriginal Research Ethics Initiative (AREI) of the Interagency Advisory Panel on Research Ethics (PRE), Issues and Options for Revisions to the Tri-Council Policy Statement on Ethical Conduct of Research Involving Humans (TCPS): Section 6: Research Involving Aboriginal Peoples (Ottawa: Interagency Advisory Panel and Secretariat on Research Ethics, 2008), online: Interagency Panel on Research Ethics (PRE) <http://www.pre.ethics.gc.ca/english/workgroups/aboriginal/Aboriginal_Peoples_Research.cfm>

(4) National Placebo Working Committee, Final Report of the National Placebo Working Committee on the Appropriate Use of Placebos in Clinical Trials (Ottawa: Canadian Institutes of Health Research, 2004), online: Canadian Institutes of Health Research <http://www.cihr-irsc.gc.ca/e/25139.html>

(5) A. Schafer, "The ethics of the randomized clinical trial" (1982) 307 New Eng. J. Med. 719.

(6) B. Freedman, "Equipoise and the ethics of clinical research" (1987) 317 New Eng. J. Med. 141.

(7) Ibid.

(8) Benjamin Freedman, "Placebo-Controlled Trials and the Logic of Clinical Purpose" (1990) 12:6 IRB: A Review of Human Subjects Research 1.

(9) Charles Weijer, "Consensus-Seeking Roundtable on Placebos in Clinical Research" (1999) 9:1 NCEHR Communique CNERH, online: NCEHR <http://www.ncehr-cnerh.org/english/communique3/consensus.html>.

(10) Supra note 2 at art. 7.4.

(11) Patricia Huston & Robert Peterson, "Withholding Proven Treatment in Clinical Research" (2001) 345 New Eng. J. Med. 912.

(12) Health Canada, Guidance for Industry: Good Clinical Practice: Consolidated Guideline ICH Topic E6 (Ottawa: Health Canada, 1997), online: Health Canada <http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/e6-eng.pdf>.

(13) International Conference on Harmonisation of Technical Requirements for Registration of Pharma--ceuticals for Human Use, ICH Harmonised Tripartite Guideline: Choice of Control Group and Related Issues in Clinical Trials E-10 (Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2000), online: ICH <http://www.ich.org/LOB/media/MEDIA486.pdf>.

(14) Canadian Institutes of Health Research, "National Placebo Initiative (NPI) Background," online: Canadian Institutes of Health Research <http://www.cihr-irsc.gc.ca/e/6849.html>.

(15) World Medical Association, World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects (Geneva: World Medical Association, 2008), online: WMA <http://www.wma.net/e/policy/pdf/17c.pdf>.

(16) Human Subject Protection; Foreign Clinical Studies Not Conducted Under an Investigational New Drug Application 73 Fed. Reg. 22800 (2008) (to be codified at 21 C. F.R. Part 312).

(17) Jonathan Kimmelman, Charles Weijer & Eric M. Meslin, "Helsinki discords: FDA, ethics, and international drug trials" (2008) 373 Lancet 13.

(18) "Sponsors' Table for Human Research Participant Protection in Canada," online: Sponsors' Table for Human Research Participant Protection in Canada <http://www.hrppc-pphrc.ca/english/sponsors.html>.

Heather Sampson, Toronto East General Hospital, Joint Centre for Bioethics, University of Toronto, Toronto, Ontario.

Charles Weijer, Professor, Department of Philosophy, University of Western Ontario, London, Ontario.

Daryl Pullman, Professor of Medical Ethics, Division of Community Health & Humanities, Faculty of Medicine, Memorial University, St. John's, Newfoundland.

Author for Correspondence: Heather Sampson, RN, CCRP, MHSc heather.sampson@utoronto.ca
COPYRIGHT 2009 Health Law Institute
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Sampson, Heather; Weijer, Charles; Pullman, Daryl
Publication:Health Law Review
Date:Mar 22, 2009
Words:3737
Previous Article:From code to policy statement: creating Canadian policy for ethical research involving humans.
Next Article:Ethical challenges and evolving practices in research on ethics in health research.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |